Renal cell carcinoma (RCC) accounts for about 3% of all human malignancies and its incidence is increasing. There are no standard biomarkers currently used in the clinical management of patients with renal cell carcinoma. A promising strategy for new biomarker detection is comparative proteomics of urinary exosomes (UE), nanovesicles released by every epithelial cell facing the urinary space, enriched in renal proteins and excluding high-abundance plasmatic proteins, such as albumin. Aim of the work is to establish the protein profile of exosomes isolated from urines of RCC patient compared with control subjects. We enrolled 29 clear cell RCC patients and 23 control healthy subjects (CTRL), age and sex-matched, for urine collection and vesicle isolation by differential centrifugation. Such vesicles were morphologically and biochemically characterized and proved to share exosome properties.
Introduction
Renal cell carcinoma (RCC), a human kidney cancer arising from the proximal tubular epithelium, accounts for 2-3% of all malignancies and is responsible for about 2% of all cancer deaths in Western countries. Among RCC, the clear-cell type displays higher frequency. Since small localized tumors rarely produce symptoms, the diagnosis of RCC is often delayed until the disease is advanced.
Moreover, RCC is associated with a high potential of metastasis and is resistant to both chemotherapy and radiotherapy, and nephrectomy remains the most effective treatment. [1] [2] [3] Molecularly targeted therapeutic options, mainly addressing products of the VHL pathway, have recently been proven to provide clinical benefits in phase III randomized clinical trials. 4 Accordingly, many RCC biomarker studies have selected components of the VHL pathway for analysis, but despite these promising advances, treatment decisions in RCC still depend on exclusively clinical criteria and there are no standard biomarkers detectable in any biological fluid currently used in the clinical management of patients with renal cell carcinoma. 5, 6 Urine is an ideal biological sample for diagnosis of urologic diseases, because of the ease and noninvasive nature of collection. Moreover, it contains proteins of renal origin and may represent the pathophysiological state of the kidney and the urologic tract.
Urinary exosomes are 30-100 nm vesicles coated with lipid bilayer membranes, derived from all types of kidney cells that contact the urinary space, including renal tubule cells. Exosomes originate in multivesicular bodies (MVBs) and are secreted into the extracellular fluid through fusion of MVBs with the plasma membrane. [9] [10] [11] The use of urinary exosomes as a starting material for biomarker discovery was shown to be advantageous, since reduction of the complexity of the urine proteome together with enrichment in renal proteins towards the plasmatic ones is achieved. 12 In fact, exosome protein content accounts for about 3% of the total proteins in normal urine, and it is depleted from the most abundant ones, such as albumin. 13 Moreover, since exosomes from different cell types have different components, it is likely that the exosome proteome could better reflect, with respect to native urine, the cellular processes associated with the pathogenesis of RCC. In fact, it was suggested that urinary exosome excretion may play a role in regulating renal epithelial protein content. 14 Accordingly, several proteomic studies on urinary exosomes have been performed to identify biomarkers predictive of urinary track diseases, both in experimental and clinical settings. 7, 13, [15] [16] [17] [18] For an exhaustive review see Moon et al. 19 However no proteomic study of urinary exosomes has been yet accomplished in RCC. Therefore, we performed MS profiling and antibody-based validation and quantification of differential proteins in urinary exosomes from a RCC patient cohort in order to search for a potential tumor marker.
Material and methods

Chemicals
Milli-Q water was used for all solutions. BCA protein assay, trifluoroacetic acid, ammonium bicarbonate, porcine trypsin DTT, iodoacetamide, Trizma-base, ACN, methanol, and CAPS were from SIGMA Chemical Co. (St. Louis, MO, USA); glycerol was from Merck (Darmstadt, Germany). Paraformaldehyde, osmium tetroxide (OsO 4 ), cacodylate buffer and LRW resin were from Electron Microscopy Sciences (Hatfield, PA, USA). The Hybond-ECL nitrocellulose membrane was from GE (Little Chalfont, Buckinghamshire, UK). NuPAGE s SDS-PAGE Gel Electrophoresis System components (mini gels, running and loading buffers, molecular weight markers and Coomassie blue staining) were supplied by Life Technologies (Paisley, Renfrewshire, UK). An anti-protease inhibitor cocktail (Complete) was from Roche (Monza, Italy). OptiPrepTM solution was from Axis-Shield (Oslo, Norway An aliquot of the collected urine samples was subjected to routine chemical-physical examination. Moreover, creatinine assay (Jaffé method, Roche) was performed on individual urine samples to normalize the gel loading of proteins to account for differences in urine concentration. 21 
Purification of exosomes
Exosomes were prepared from each patient's urine sample by differential centrifugation 22 and according to guidelines provided by EuroKUP (http:www.eurokup.org). Briefly, after sediment removal (10 min at 1000 Â g, 4 1C) and addition of protease inhibitors (Complete, Roche), urine samples were G  pT  Number of patients   1  2 a  1  1a  5  2  1 b  1 0  2a  6  2-3  1b  1  1a  1  1b  3  3  2 a  1  2b  1 centrifuged for 15 min at 17 000 Â g and 4 1C, to eliminate large membrane fragments and debris. Supernatants were subjected to ultracentrifugation for 1 h at 200 000 Â g and 4 1C: crude exosome pellets were washed in PBS and then resuspended in bidistilled water, in the presence of protease inhibitors. The samples were stored at À80 1C until use. In some cases, in order to verify the efficacy of further purification, the crude exosomes were subjected to Optiprep TM density gradient ultracentrifugation. 23 Briefly, the crude exosome pellet was overlaid on a discontinuous OptiPrep gradient (40, 20, 10 , and 5% OptiPrep solution in 0.25 M sucrose, 10 mM Tris, pH 7.5) and centrifuged at 100 000 Â g for 16 h. Twelve fractions (1 mL) were collected from the top of the gradient, diluted with 2 mL of 10 mM Tris buffer, and centrifuged at 100 000 Â g for 3 h; after washing with PBS, the obtained pellets were subjected to further analysis. The density of each fraction was determined by absorbance at 244 nm using a duplicate parallel discontinuous OptiPrep gradient overlaid with 500 mL of 0.25 M sucrose, 10 mM Tris, pH 7.5.
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Moreover, we analyzed the protein composition of urine samples after sediment removal (U), and of the supernatants after 200 000 Â g ultracentrifugation (Sn).
In order to concentrate proteins, urine and Sn samples were subjected to ultrafiltration: briefly, 500 mL of urine samples were loaded onto concentrator devices, VivaSpin 500 (3000 MW cut-off PES membrane, Sartorius), pre-treated with 5% Triton-X100 for improved recovery of low-concentrated samples, according to the manufacturer's instruction. After a 45 min centrifugation at 15 000 Â g (4 1C), the concentrate was collected and lyophilized.
Protein concentration was assessed by BCA assay (Sigma). For protein identification and deglycosylation experiments, representative UE derived from 9 RCC and 9 CTRL urine samples were pooled and proteins separated by 4-12% gel electrophoresis, followed by LC-MS/MS analysis.
Transmission electron microscopy
In order to validate exosome purity, Transmission Electron Microscopy (TEM) imaging of exosomes was performed as below. Briefly, after exosome purification, fresh exosomal preparations were fixed with 4% paraformaldehyde and deposited on Formvarcarbon-coated Nickel grids. Samples were post-fixed in 1% OsO4 in cacodylate buffer, dehydrated in ethanol and embedded in LRW resin. Grids were doubly stained with uranyl acetate and lead citrate and examined using a transmission electron microscope CM 10 Philips (FEI, Eindhoven, the Netherlands).
Deglycosylation of exosome proteins
Removal of N-and O-linked glycans was performed using the Glycoprotein Deglycosylation kit (Merck, Nottingham, UK) according to the manufacturer's instructions. 25 Briefly, proteins (15 mg) from pooled RCC and CTRL exosomes were dissolved in reaction buffer (50 mM sodium phosphate buffer, pH 7.0) in the presence of anti-proteases. Proteins were incubated with denaturing solution (0.2% w/v SDS, 100 mM b-mercaptoethanol), at 100 1C for 5 minutes; then, Triton X-100 (0.75%) was added to complex any free SDS. Enzymatic deglycosylation was carried out by the addition of 1 mL of PNGase F (5000 U mL À1 ), 1 mL of endo-
, and 1 mL of b-1,4-galactosidase (3.0 U mL
À1
), and samples were incubated overnight at 37 1C. Bovine fetuin was deglycosylated under the same conditions, and used as a control.
Electrophoresis and western blotting
Equal amounts of exosome, urine and Sn proteins were separated by 4-12% NuPAGE (Life technologies) and transferred to nitrocellulose membranes, using a mini transfer tank (Hoefer). After blocking with 5% free-fat milk/0.2% Tween 20 in PBS solution, the blots were developed with the respective primary antibodies followed by a peroxidase-conjugated secondary antibody (Pierce) and enhanced chemiluminescence detection (SuperSignal West-Dura ECL, Pierce) by a CCD camera (Kodak ds Image Station 2000 R). Densitometric analysis was performed by molecular Imaging Software (Kodak) and the volumes of band proteins were normalized to urinary creatinine content.
14 Evaluation of diagnostic performance was accomplished by ROC analysis (GraphPad Prism 5, GraphPad Software, Inc.).
For mass spectrometry analysis, pooled exosome proteins were separated using a 4-12% NuPAGE electrophoresis system (Life Technologies), and subjected to Coomassie Blue staining.
Mass spectrometry and protein identification
The bands of interest were excised from gels and subjected to in-gel protein digestion as already described by Raimondo et al. 26 Briefly, the gel plugs were washed twice with a mixture of 25 mM NH 4 HCO 3 -ACN (1 : 1; v/v) for 15 min. After 45 minute reduction at 56 1C with 10 mM DTT, protein bands were alkylated with 55 mM of IAA (dark; 30 min). Gel slices were then washed again using ammonium bicarbonate, 25 mM, with 50% acetonitrile for three times. After dehydration with acetonitrile, the proteins were in-gel digested with modified porcine trypsin (Promega, Madison, WI, USA; 12.5 ng mL À1 in 25 mM NH 4 HCO 3 ) at 37 1C overnight (8 mL for each sample). Digested peptide solutions were then diluted in TFA 0.1% and the entire volume was injected into nLC ESI MS/MS. Protein identification was performed on a Proxeon EasynLC System (Proxeon Biosystems, Odense, Denmark) coupled with a MaXis hybrid UHR-QToF system (Bruker Daltonics, Bremen, DE). After injection, trypsinized samples were thus desalted onto a 2 cm precolumn (ID 100 mm, 5 mm, C18-A1, EasycolumnTM, Proxeon) and separated with a flow of 300 nL min À1 on a 10 cm fused silica micro-capillary analytical column (ID 75 mm, 3 mm, C18-A2, EasycolumnTM, Proxeon) using a 60 min gradient from 2 to 56% of acetonitrile containing 0.1% of formic acid in 25 min and then from 56 to 98% in 10 min. The EasynLC column was directly connected to the ESI source with a nanosprayer system (Bruker Daltonics, Bremen, DE). MS level measurements were all performed on a predefined 50-2200 m/z acquisition window at 1 Hz spectra rate. To improve mass accuracy a specific lock mass (1221.9906 m/z) was used. CID MS/MS acquisition was performed over a 400-1600 m/z window (excluding 1221.5-1224 m/z) with five intensity binned View Article Online precursors of preferred charge state range +2 to +4, with at least 2000 counts selected for fragmentation. Selected precursors that had been analysed more than once were actively excluded from analysis for 30 s. Isolation width and collision energy were applied on the basis of isolation mass value and charge state against a table of isolation and fragmentation lists fitted for tryptic peptides. The total cycle time ranged from 6 to 11 seconds. Ion transmission for MS-MS was also performed by setting key parameters for the collision cell and the ion cooler cell as follows: CCRF = 1200 Vpp and ICRF = 400 Vpp; transfer time ICTT = 100 ms and pre-pulse time ICPP = 8 ms.
Raw MS/MS data were lock-mass corrected, deconvoluted and converted to an XML peaklist via Compass DataAnalysis v.4.0 Sp4 (BrukerDaltonics). Peakfinder (sumpeaks) was set to exclude any ions with S/N o 1 and intensity o20 counts. In house Mascot search engine (Version: 2.3.02) was used for processing XML data. Database searching was restricted to the human Swissprot (accessed Feb 2012; 20,317 sequences) database. Searches were performed against the database using the following parameters: fully tryptic enzymatic cleavage with one possible missed cleavage, a peptide tolerance of 10 ppm, and a fragment ion tolerance of 0.5 Da. Fixed modification was set as carbamidomethyl due to carboxyamidomethylation of cysteine residues. Mascot threshold scores for identity were used as peptide level filters of peptide significance. Protein identifications with a Mascot score above the significant hit threshold (p o 0.05) and at least one identical peptide were considered significant.
Results and discussion
Urinary vesicle isolation and characterization
Urine samples were collected from 29 RCC patients and 23 healthy controls, matched for sex and age. The patients display quite homogeneous clinical features, most of them were in early phases of disease, with no metastasis nor positive lymph nodes at the moment of diagnosis (Table 1; Tables S1 and S2 in ESI †).
All the patient and control subject urine samples were negative for proteins, glucose, ketone, bilirubin, urobilinogen, and blood.
After urinary vesicle isolation, their protein concentration was assessed, and referred to the initial urine volume (Tables S1  and S2 in ESI †). It is highly variable, as already reported, ranging from 0.99 to 16 mg mL À1 of starting urine samples in patients, and from 2.78 to 11.8 mg mL À1 in controls. 27 In order to validate the exosome purification protocol, we performed western blot analysis on the ultracentrifugation pellets, in comparison with starting urine samples and the ultracentrifugation supernatants (after suitable protein concentration), using antibodies against three commonly used urinary exosomal markers, CD9, TSG101 and Flotillin-1. 28 Results show that urinary exosome-associated protein signals were predominant in the vesicle fraction, and nearly undetectable in total urine or the supernatant (Fig. 1A) . Therefore markers are highly and reproducibly enriched in the vesicle fraction, both in RCC and in controls (Fig. 1B) . It has been reported 29 that efficient isolation and purification of urinary exosomes facilitate quantitative and reproducible proteomic investigation. However, this is obtained at the expense of a very low recovery, and leads to the requirement of huge amounts of starting material (as much as 1 L of urine samples). This seems quite unsuited with the clinical needs. Indeed, our results obtained by the application of a more stringent isolation method (Optiprep gradient) show that exosome markers are mainly detectable in fraction 7, at a density of 1.10 g mL À1 , as reported. 30 However, it did not lead to a substantially increased enrichment (Fig. S1 in the ESI †), compared with an ultracentrifugation protocol (CE, crude exosomes), while the yield was much lower. Moreover, UE morphology, shape and dimension were examined by electron microscopy, followed by morphometric analysis. Vesicles are shown to have spherical shape and mean diameter comprised between 30 and 50 nm, indicating that the population of vesicles, prepared by UC, which we are dealing with, is constituted mainly of real exosomes; in fact, the spherical shape and the mean dimensions ( Fig. 2 and 3 ) agree with data present in the literature. 30 Moreover, there are no important morphological differences between exosomes in the two groups (patients and controls), as shown also by the morphometric analysis ( Fig. 2A, B and 3 ). Also in this case, when we further purified vesicles by the Optiprep gradient, we did not observe any substantial change in the vesicle appearance, except for the presence of a cleaner background (Fig. S2 in the ESI †), confirming data regarding marker enrichment. Accordingly, we concluded that the crude preparations contain ''bona fide'' exosomes.
Electrophoresis analysis
In this study, the molecular weight distribution of UE proteins was observed by NuPAGE, followed by Coomassie Blue staining. As shown in Fig. 4 , the distribution of protein bands following gel electrophoresis was similar in starting urine and in the supernatant after centrifugation at 200 000 Â g; instead, the distribution of protein bands was different in UE samples, determining a typical protein profile: in fact albumin, responsible for the main band appearance in the non-exosomal fractions, results depleted, while THP, a glycoprotein released by kidney tubular cells, is predominant in the UE profile, although with different intensity in the different lanes (see also Fig. 5 ). The variable content of THP may also explain the variations encountered in total protein UE recovery (see above). Moreover, apart from THP, the exosomal protein composition was similar inside the same group (of RCC patients and healthy controls), while it showed evident differences between these two groups (Fig. 5) . We also checked that the stability of the similarity and the reproducibility of the differences were independent of the time of collection (data not shown). Therefore a consistent reproducibility is assured (Fig. 5) .
Relying on this observation, we selected some representative UE samples for pooling, aimed at proteomic analysis, before and after enzymatic deglycosylation. Deglycosylation determined substantial changes in the UE protein profile, with an evident shift of THP glycoprotein bands towards lower molecular weights (Fig. S3 in ESI †) .
Protein identification
In order to investigate the RCC and healthy control UE protein profiles, we prepared a pool of UE from 9 different patients and another one from 9 healthy subjects. This allowed us to have enough material and to reduce the effect of interpersonal variability. We identified 261 proteins in CTRL subjects' UE and 186 in RCC patients' UE, some of which only after deglycosilation, likely due to the uncovering of some bands and the Mascot score = Mascot threshold scores for identity were used as peptide level filters of peptide significance. Protein identifications with a Mascot score above the significant hit threshold (p o 0.05) and at least one identical peptide were considered significant. Localization = subcellular localization based on UniProtKB. View Article Online sharpening of others (Fig. S3 , Tables S3 and S4 in ESI †). About 44% of total identified proteins (147/333) are present only in CTRL, while about 22% are detected only in RCC UE (72/333), suggesting the occurrence of a differential protein content in the two groups (Tables 2 and 3 ). About 75% of identified proteins is present also in Exocarta -an updated database reporting all the identified exosome molecules -in the section regarding UE. 31 However, it is worth noting that a good percentage of identified proteins (about 25%) is not yet reported in Exocarta (Fig. 6) . The cellular localizations of the identified proteins (Fig. 7A ), based on UniProtKB, an Expasy resource, indicate that the majority of them are in the plasma membrane, in vesiclerelated organelles (e.g. cytoplasmic and membrane bound vesicles, early and late endosomes, lysosomes, secretory granules, and ER-Golgi intermediate compartment), and in the cytoskeleton. Moreover, in the RCC exosome pool, a high percentage (35%) is represented by secreted proteins, while it is reduced (only 15%) in CTRL ones.
The identified proteins were also analysed from a functional point of view (Fig. 7B) , and we assessed the presence of many typical exosomal proteins, such as the component of the ESCRT machinery (TSG101), proteins involved in trafficking View Article Online and membrane fusion (annexins), and tetraspanins such as CD9, possibly correlated to the exosome biogenesis mechanism. 30 Moreover, many other functional classes were recognized, such as metabolic enzymes (i.e. triosophosphate isomerase, isocitrate dehydrogenase), proteins involved in signalling (i.e. Ras-related proteins), related to cellular adhesion and motility (i.e. ezrin, syntenin 1), communication (G-proteins), and transport (i.e. chloride intracellular channel protein 1 CLIC1). The presence of these proteins highlights the UE cellular origin. A consistent difference between the two pools concerns the percentage of immunity related proteins. In fact they are 18% for RCC and 7% for control exosomes. Although it must be considered that each protein is counted once in this classification, regardless of its absolute content, this result may be related to the activation of the immune system encountered in neoplastic diseases, and to one of the putative functions of exosomes, which is immune system regulation. Furthermore, many species in this group belong to the immunoglobulin family, providing a possible explanation for the above reported increase of secreted proteins in tumour exosomes. Despite the well-known involvement of angiogenesis in RCC, only a few proteins related to this function were found in our proteomic analysis of urinary exosomes. A possible explanation for this finding is that the tumour cells may retain such strategic molecules, or release them towards the internal microenvironment; 32 on the other hand, it has to be underlined that our analytical condition did not allow for the identification of low abundant UE proteins. Moreover, the fact that urinary exosomes are not a preferred vehicle for these kinds of molecules is also suggested by their under-representation in an extensive list of UE proteins recently published.
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When we compared the enrichment of the biological functions on the same scale (by Ingenuity Pathway Analysis resource), the analysis showed that the profile of biological functions associated with RCC UE proteins differs considerably from CTRL ones (Fig. 8) . In fact, the species related to cell death, scavenger of free radicals and cellular movement are more enriched in pathological UE, while molecular transport class is enriched in controls.
Western blot
To further validate the differential proteomic profiles of UE from RCC patients compared to controls, we examined some View Article Online protein levels in UE. Protein selection was based on several criteria including (1) our previous results obtained by gene and protein expression profiling on RCC tissue samples; 26, 34 (2) their potential roles in contributing to RCC diagnosis, and (3) the availability of commercial antibodies. Based on the above criteria, we selected a panel of 10 proteins, and subjected their UE differential content to validation using western blot analysis (Fig. 9A) . After densitometric quantification of band intensity, results were expressed as DO per mg of creatinine in Fig. 9B . Results show that Matrix metalloproteinase 9 (MMP-9), Ceruloplasmin (CP), Podocalyxin (PODXL), Dickkopf related protein 4 (DKK4) and Carbonic Anhydrase IX (CAIX) are significantly more abundant in RCC patient UE, while Aquaporin-1 (AQP1), Extracellular Matrix Metalloproteinase Inducer (EMMPRIN), Neprilysin (CD10), Dipeptidase 1 and Syntenin-1 display a significant reduced content in RCC patient's UE. MMP9, DKK4 and EMMPRIN are involved in extracellular matrix remodeling. [35] [36] [37] Moreover, it has been reported that these three proteins are overexpressed in RCC and correlate with RCC aggressiveness and high RCC metastatic potential by promoting tumor cell migration and invasion. 26, 36, 38, 39 Accordingly, the MMP9 and DKK4 increased content in RCC UE could be correlated to these features. This hypothesis is supported by a recent paper showing that exosomes derived from gynecologic neoplasias contain metalloproteinases that increase extracellular matrix degradation and augment tumor invasion into the stroma. 36 In contrast, EMMPRIN could be retained by tumor cells, because of its capability to induce the activation of the extracellular matrix metalloproteases such as MMP9, thus explaining its reduced content in RCC urinary exosomes, compared to control ones. PODXL and AQP1 are typical proteins expressed by human kidney: PODXL is highly expressed in podocytes and is important for the maintenance of the cellular morphology and the anti-adhesive properties of these cells, 40 while AQP1 is a membrane water channel physiologically expressed by the proximal tubule and the loop of Henle. AQP1 (both mRNA and protein) was reported to be downregulated in RCC tissues. 41, 42 Its reduction may be related to the loss of cellular specialization, a sort of ''dedifferentiation'' strategy; this could explain also its decreased content in UE. PODXL, in contrast, has recently emerged as a malignant marker in tumors arising from a variety of tissues, including also RCC. 43 Syntenin-1, in contrast to PODXL, is reported to be involved in the cellular adhesion by coupling the syndecan-2 to the cytoskeleton. 44 It is expressed, among other tissues, also in the kidney, and is a typical exosomal protein.
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DPEP1 is important for the physiological activity of renal cells, in particular in glutathione metabolism; for this reason it may be eliminated in urinary exosomes by tumour cells as another possible strategy to promote tumor development and progression, due to the reduction of the free radical detoxification power. 45 Neprilysin (CD10) is normally expressed by the proximal tubules and by the glomerular epithelial cells: it is a zinc-dependent metallopeptidase, which is involved in the metabolism of a number of regulatory peptides and plays an important role in turning off peptide signalling at the cell surface. 46 Loss or decrease in neprilysin expression has been reported in many types of malignancies, including renal cancer. 34, 47 DPEP1 and CD10 demonstrate to have a reduced content in RCC UE, compared to control ones, possibly according to the loss of the cellular specialization, as already mentioned. Finally, the levels of CAIX and CP are found significantly increased in RCC urinary exosomes: it has to be underlined that their promoters were reported to be activated by the transcriptional factor HIF-1a, known to be involved in RCC genesis. [48] [49] [50] In particular, gene expression profiling on renal tissue showed a marked CP mRNA overexpression in RCC patients compared to controls, 34, 51 while CAIX is proven to be a powerful tissue marker for ccRCC and was recently shown to correlate with tumor size. 52 Both CP and CAIX have been detected in RCC patient serum. 52, 53 Summarizing, protein profiling and validation results indicate that the pattern of RCC UE resembles that of cancer tissue for some proteins, but it displays quite distinctive and specific features overall. As such, our data indicate that the RCC patient's UE protein profile significantly differs from that of control subjects (Fig. 10) . It has to be underlined that also the RCC UE lipid composition was recently demonstrated to be differential, 54 providing further evidence for a relationship between UE composition and RCC disease. Western blot results were then used to generate ROC curves, to predict the potential impact for use of the biomarker candidates in discriminating between the RCC group and the controls; the AUC values were determined for each protein and range between 0.73-1. In particular, CP and PODXL resulted to have AUC equal to 1, suggesting to be best at distinguishing RCC patients from the control group. The ROC curves and the AUC values of the other 8 proteins are shown in Fig. 11 . Thus, these results could constitute a basis for the set-up of a multimarker strategy in UE for RCC detection. This approach would guarantee a more valid diagnostic result compared to the single markers, because less dependent upon the inter-individual differences, typical of polygenic diseases. In fact, although CP seems to have the best diagnostic performance, in AUC terms, it has been suggested that its increase in RCC serum could be part of an acute phase response to the cancer as an unspecific marker of inflammation. 53 Moreover, it is likely that the use of multiple markers will assure a better specificity towards clear cell RCC, than the single one: the assessment of this hypothesis deserves further investigation. Finally, in order to get a more comprehensive portrait of differential RCC protein abundance in exosomes, an appealing solution is represented by a protein microarray format along with western blot. It could give sensitive, real-time and multiplexed detection on a targeted set of specific proteins, and would allow us to validate a panel of discriminating proteins. Then the protein microarray could be easily used for diagnosis or post-surgery monitoring of RCC. We intend to evaluate this approach in a future work.
Concluding remarks
To the best of our knowledge, this is the first proteomic study performed on urinary exosomes obtained from RCC patients. Taken together, the present results show that (1) due to their biochemical and morphological characteristics, vesicles isolated by ultracentrifugation from urine samples collected from patients and controls are enriched in ''bona fide'' exosomes; (2) UE proteome represents a peculiar and readily isolated subset of the urinary proteome, and is enriched in cell-derived proteins, which may possibly be involved in the RCC pathogenesis or progression; (3) RCC UE protein content is substantially and reproducibly different from the control UE one.
In conclusion, our work suggests that exosome isolation may provide an efficient first step in RCC biomarker discovery in urine.
